About us Contacts Drug interactions: 390 212
Drug search by name

Jevantique Lo and Thalomid

Determining the interaction of Jevantique Lo and Thalomid and the possibility of their joint administration.

Check result:
Jevantique Lo <> Thalomid
Relevance: 22.12.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using thalidomide together with ethinyl estradiol may increase the risk of dangerous blood clots. The risk is higher if you are using thalidomide with dexamethasone or other chemotherapy drugs for the treatment of multiple myeloma than if you are using thalidomide alone for some other condition. Also, the risk is increased with age, cigarette smoking, high blood pressure, or high cholesterol. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, difficulty breathing, coughing up blood, sudden loss of vision, and/or pain, redness or swelling in an arm or leg. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use of thalidomide. When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving thalidomide with dexamethasone versus 4.9% in patients receiving dexamethasone alone. Arterial thromboembolism such as myocardial infarction and cerebrovascular event may also occur. The risk of thromboembolism appears to be greatest during the first five months of therapy.

MANAGEMENT: The use of estrogen-containing medications including combined oral contraceptive pills should be undertaken with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids. Patients should be apprised of potentially increased risk of venous thromboembolic events if a combined oral contraceptive pill is chosen as one of two effective methods of contraception that must be used simultaneously and continuously for 4 weeks before, during (even in case of dose interruption), and for 4 weeks after thalidomide therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of thalidomide treatment. Because some patients receiving thalidomide may also develop sudden, severe neutropenia and/or thrombocytopenia, hormonal contraceptives that are implanted may carry an increased risk for infection or bleeding either at insertion, removal, or during use.

References
  • "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Jevantique Lo

Generic Name: ethinyl estradiol / norethindrone

Brand name: femhrt 05 mg/25 mcg, Fyavolv, Jevantique Lo, Jinteli, Blisovi 24 Fe, Estrostep Fe, Femcon Fe, Kaitlib FE, Lo Minastrin Fe, Microgestin 24 Fe, Norinyl 1+35, Ortho-Novum 7/7/7, Taytulla, Tri-Norinyl, Zenchent, Blisovi 24 Fe, Blisovi Fe 15/30, Blisovi Fe 1/20, Gildess 24 Fe, Gildess Fe 15/30, Gildess Fe 1/20, Junel Fe 15/30, Junel Fe 1/20, Junel Fe 24, Larin 24 Fe, Larin Fe 15/30, Larin Fe 1/20, Lo Loestrin Fe, Loestrin 24 Fe, Loestrin Fe 15/30, Loestrin Fe 1/20, Lomedia 24 Fe, Microgestin 24 Fe, Microgestin Fe 15/30, Microgestin Fe 1/20, Tarina Fe 1/20, Tilia Fe, Tri-Legest Fe, Femcon Fe, Generess FE, Loestrin 1/20, Ovcon 35, Brevicon

Synonyms: Jevantique Lo (HRT)

Thalomid

Generic Name: thalidomide

Brand name: Thalomid

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction